Plasma p-tau217, amyloid-β-42/40, NfL and GFAP were measured in 5,913 cognitively normal Netherlands Twin Register adults aged 30 to 80. The study tested how APOE ε4, a polygenic risk score excluding APOE, age and sex related to these biomarkers. Carriers and non-carriers diverged at 53.2 years for amyloid-β-42/40, 58.8 for p-tau217 and 62.8 for GFAP, but not for NfL. The polygenic risk score did not alter how any biomarker changed with age. In 202 older twins with amyloid PET scans, p-tau217 rose faster where amyloid was present. Carrying ε4 was linked to an earlier rise. The main cohort was cross-sectional and family-based, and cognition was not formally tested.
Why it is interesting: Plasma p-tau217, amyloid-β-42/40 and GFAP differed by APOE ε4 status 15 to 20 years before estimated mean clinical onset. These differences appeared in adults reporting no memory complaints.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.